MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'inhibitor'. Sat, 03 Sep 2011 02:11:41 +0100 http://www.medworm.com/index.php?rid=5181801&cid=t_145620_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fapixaban-finally-showing-superiority-over-warfarin-in-clinical-trial%2F2011.09.01 With the publication of “Apixaban versus Warfarin in Patients with Atrial Fibrillation” (the ARISTOTLE trial) in the New England Journal of Medicine, the third drug in a series of medications designed to attack thrombin in the clotting cascade. The study was announced with quite a fanfare in Europe as cardiologists, financial analysts and reporters gushed forth with ‘mega-blockbuster’ praise this past weekend. And for good reason. This is the first trial to conclude that (more…) *This blog post was originally published at Dr. Wes* (Source: Better Health) Better Health blogs http://www.medworm.com/rss/comments.php?id=5181801 Thu, 01 Sep 2011 14:00:00 +0100 5181801 http://www.medworm.com/index.php?rid=4893809&cid=t_145620_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F06%2F03%2F2011-asco-entremed%25e2%2580%2599s-enmd-2076-demonstrates-clinical-activity-in-recurrent-platinum-resistant-ovarian-cancer-patients%2F EntreMed, Inc. announced that ENMD-2076 demonstrated clinical activity — a six-month progression free survival rate of 19% – when administered as a single agent to platinum drug-resistant recurrent ovarian cancer patients. The announcement is based upon interim phase 2 data presented today at the 2011 American Society of Clinical Oncology Annual Meeting.  EntreMed, Inc., a clinical-stage [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4893809 Sat, 04 Jun 2011 05:10:24 +0100 4893809 http://www.medworm.com/index.php?rid=4653509&cid=t_145620_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2011%2F03%2F28%2Fphenoxodiol-used-in-combination-with-platinum-or-taxane-based-chemotherapy-is-active-in-platinum-taxane-resistant-ovarian-cancer%2F Phase II clinical study results suggests phenoxodiol is active in platinum and taxane drug-resistant ovarian cancer patients when administered intravenously in combination with platinum or taxane-based chemotherapy Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, recently announced the publication of results from a phase II clinical [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4653509 Tue, 29 Mar 2011 04:23:51 +0100 4653509 http://www.medworm.com/index.php?rid=4482972&cid=t_145620_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FTPwrSwUNAKo%2F Good morning, everyone. Nice to see you again. A sunny day is unfolding here on the Pharmalot corporate campus, where we are happily quaffing our mandatory cup of stimulation. This will be an especially busy day as we must break for a personal matter, but we will endeavor, nonethless, to hunt about for interesting items. Meanwhile, we would like to remind you that we are hosting a webinar on requirements for disclosing payments to physicians (look here). See you soon… Sanofi-Aventis To Buy Genzyme For $20 Billion (Bloomberg News) Sanofi-Aventis Will Withdraw Anzement From Five Countries (Dow Jones) Merck No Longer Has Buyer For Dutch R&D Unit (Reuters) Takeda Strikes Deal With Covance And Quintiles (Outsourcing Pharma) Generic Drugmakers To Support FDA User Fees (Wall Street Jou... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4482972 Wed, 16 Feb 2011 12:56:39 +0100 4482972 http://www.medworm.com/index.php?rid=4455224&cid=t_145620_86_f&fid=36669&url=http%3A%2F%2Ffadelibrary.wordpress.com%2F2011%2F01%2F26%2Fjournal-of-the-medical-association-2010-vol-304-no-3%2F The objective of this article is to determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother of menopausal hot flushes. The article concludes that among healthy women, the use of escitalopram (10-20 mg/d) compared with placebo resulted in fewer and less severe menopausal hot flushes at 8 weeks of follow-up. An NHS Athens password is required to access this article online, alternatively contact the Library for a copy of this article. Filed under: Athens Password, E-Journals Tagged: Antidepressants, Menopausal Symptoms, Selective Serotonin Reuptake Inhibitor, SSRI, United States (Source: Fade Library) Fade Library blogs http://www.medworm.com/rss/comments.php?id=4455224 Wed, 26 Jan 2011 12:21:24 +0100 4455224 http://www.medworm.com/index.php?rid=4411486&cid=t_145620_86_f&fid=36669&url=http%3A%2F%2Ffadelibrary.wordpress.com%2F2011%2F01%2F26%2Fjournal-of-the-medical-association-2010-vol-304-no-3%2F The objective of this article is to determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother of menopausal hot flushes. The article concludes that among healthy women, the use of escitalopram (10-20 mg/d) compared with placebo resulted in fewer and less severe menopausal hot flushes at 8 weeks of follow-up. An NHS Athens password is required to access this article online, alternatively contact the Library for a copy of this article. Filed under: Ooops Missed Category! Tagged: Antidepressants, Menopausal Symptoms, Selective Serotonin Reuptake Inhibitor, SSRI, United States (Source: Fade Library) Fade Library blogs http://www.medworm.com/rss/comments.php?id=4411486 Wed, 26 Jan 2011 12:21:24 +0100 4411486 http://www.medworm.com/index.php?rid=4399463&cid=t_145620_86_f&fid=36669&url=http%3A%2F%2Ffadelibrary.wordpress.com%2F2011%2F01%2F26%2Fjournal-of-the-medical-association-2010-vol-304-no-3%2F The objective of this article is to determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother of menopausal hot flushes. The article concludes that among healthy women, the use of escitalopram (10-20 mg/d) compared with placebo resulted in fewer and less severe menopausal hot flushes at 8 weeks of follow-up. An NHS Athens password is required to access this article online, alternatively contact the Library for a copy of this article. Filed under: Ooops Missed Category! Tagged: Antidepressants, Menopausal Symptoms, Selective Serotonin Reuptake Inhibitor, SSRI, United States (Source: Fade Library) Fade Library blogs http://www.medworm.com/rss/comments.php?id=4399463 Wed, 26 Jan 2011 12:21:24 +0100 4399463 http://www.medworm.com/index.php?rid=4163029&cid=t_145620_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F11%2F12%2Fovarian-cancer-drug-amg-386-shows-promise-with-move-to-phase-3-trials-in-australia-canada-europe%2F A new drug (AMG 386) designed to arrest ovarian cancer cell growth by inhibiting blood vessel formation is being readied for a phase 3 trial in Australia, Canada and Europe. AMG 386, a new drug designed to arrest ovarian cancer cell growth by inhibiting blood vessel formation, is being readied for a phase 3 trial [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=4163029 Fri, 12 Nov 2010 21:27:07 +0100 4163029 http://www.medworm.com/index.php?rid=3946655&cid=t_145620_136_f&fid=37846&url=http%3A%2F%2Fwww.phsa.ca%2FNR%2Frdonlyres%2F825EDD83-D53B-433C-8012-C7737B89CA50%2F0%2FHuntsmanedit.mp3 British Columbian researchers discover that approximately one-half of clear-cell ovarian cancers and one-third of endometrioid ovarian cancers possess ARID1A gene mutations, as reported today in the New England Journal of Medicine. British Columbian researchers discover that approximately one-half of ovarian clear-cell cancers (OCCC) and one-third of endometrioid ovarian cancers possess ARID1A (AT-rich interactive domain 1A [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3946655 Thu, 09 Sep 2010 01:28:12 +0100 3946655 http://www.medworm.com/index.php?rid=3816657&cid=t_145620_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F08%2F03%2Flargest-study-matching-genomes-to-potential-anticancer-treatments-releases-initial-results%2F The largest study to correlate genetics with response to anticancer drugs released its first results on July 15. The researchers behind the study, based at Massachusetts General Hospital Cancer Center and the Wellcome Trust Sanger Institute, describe in this initial dataset the responses of 350 cancer samples (including ovarian cancer) to 18 anticancer therapeutics. U.K.–U.S. [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3816657 Wed, 04 Aug 2010 03:43:59 +0100 3816657 http://www.medworm.com/index.php?rid=3790922&cid=t_145620_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FD6X1iIXfZM4%2F Medicare Part D may be helping more older Americans with heart failure get meds used to control the disease. A new study of nearly 7,000 older heart failure patients in a big insurance plan found the number of filled prescriptions for standard heart failure meds increased after Part D began in 2006, and the biggest increase was among seniors who previously lacked drug coverage. The results, which were reported in the American Heart Journal, are the first to show Part D may help more people with heart failure get meds that are recommended to lower the risk of hospitalization and extend lives. The findings, Reuters writes, suggest concerns that drugmakers would be the largest beneficiaries from the program may be unfounded. You may recall that a 2007 report by IMS Health found Part D boosted... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3790922 Mon, 26 Jul 2010 12:08:25 +0100 3790922 http://www.medworm.com/index.php?rid=3730043&cid=t_145620_136_f&fid=36032&url=http%3A%2F%2Fwww.everydayhealth.com%2Fblog%2Flife-with-breast-cancer%2Fpharmacists-can-help-in-the-battle-against-breast-cancer%2F One great source of support for me during and after breast cancer was my pharmacy. I had a wonderful community pharmacy with really helpful pharmacists and assistants. Whenever I showed up with a new prescription, the pharmacist would take the time to answer my questions and review the information about the medication. Since early this year I have been wrestling with taking Femera. I wrote about it in a blog after my oncologist prescribed it in January. I was supposed to start taking it right after I finished taking tamoxifen in March. Well, as much as I appreciate the encouragement I received from readers and the continued nagging from my doctor, here I am still trying to decide if I should take it. I haven’t gone in to talk to my regular pharmacist yet because if I am not prepared to s... Life with Breast Cancer blogs http://www.medworm.com/rss/comments.php?id=3730043 Tue, 06 Jul 2010 17:54:57 +0100 3730043 http://www.medworm.com/index.php?rid=3718646&cid=t_145620_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F07%2F01%2Fbms-345541-dasatinib-resensitizes-carboplatin-resistant-recurrent-ovarian-cancer-cells%2F Johns Hopkins medical researchers discovered through proteomic analysis that RELA and STAT5 are upregulated in carboplatin resistant ovarian cancer cells, according to a published study appearing in the June 18 edition of PLoS One. Moreover, the researchers also demonstrated that BMS-345541 (a NF-kappaB inhibitor) and dasatinib (a STAT5 inhibitor) could resensitize carboplatin-resistant, recurrent ovarian cancer [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3718646 Fri, 02 Jul 2010 02:53:34 +0100 3718646 http://www.medworm.com/index.php?rid=3287419&cid=t_145620_139_f&fid=38879&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FVirologyBlog%2F%7E3%2FKsK0AgKil_M%2F Broad spectrum antibiotics are available that act against a wide range of bacteria, including both gram-positive and gram-negative species. In contrast, our antiviral arsenal is exceedingly specific. Nearly all the known antivirals block infection with one or two different viruses. The discovery of a compound that blocks infection with many different enveloped viruses may change the landscape of antiviral therapy. A small molecule has been discovered that inhibits infection by a wide range of viruses with membranes, the so-called enveloped viruses. The compound, called LJ001, is a derivative of aryl methylene rhodanine. It was discovered in a search for compounds that block the entry of Nipah virus into cells. LJ001 was then found to block infection of cells by a wide variety of enveloped ... virology blog blogs http://www.medworm.com/rss/comments.php?id=3287419 Thu, 18 Feb 2010 22:59:23 +0100 3287419 http://www.medworm.com/index.php?rid=2886649&cid=t_145620_131_f&fid=34989&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FGeneticsHealth%2F%7E3%2FR7LcuCQ5FUE%2F Hereditary angioedema (HAE) is a potentially fatal genetic disorder caused by a deficient or abnormal blood protein called C1 inhibitor. It causes swelling of the extremities, face, trunk, abdomen or airways. Abdominal attacks can result in severe pain, nausea, vomiting, cramps and diarrhea. The attacks can be spontaneous but may also be triggered by stress, surgery or infection. Death may result when the airways close because of the swelling. Only 1 in 50,00 to 150,000 people worldwide/ 1 in 10,000 to 50,000 in the US is affected by this rare dominant mutation, but the mortality is quite high (30%) so it’s really good that the U.S. Food and Drug Administration has approved a treatment Hereditary angioedema. The FDA announced that Berinert has been approved for adults and adolescents wi... Genetics and Health blogs http://www.medworm.com/rss/comments.php?id=2886649 Tue, 13 Oct 2009 03:58:27 +0100 2886649 http://www.medworm.com/index.php?rid=4060671&cid=t_145620_109_f&fid=34859&url=http%3A%2F%2Fblog.davemsw.com%2Farchives%2F2009%2F09%2Fgenerics_versus_brands_are_they_really_the_same.php This is a topic that gets scant attention leaving the consuming public largely in the dark. Even though I work in the field, I've not hear this information except from my own reading. Fortunately, SSRIs are not as susceptible to problems crossing from brands to generics or between generics. But buproprion in other forms may not be as good as Wellbutrin. Image via WikipediaMedical News "Antidepressant and antipsychotic drugs have become blockbusters for the firms that developed them, making them hot markets for generic competition. Moreover, the effectiveness of these drugs is measured in the same way as anticonvulsants -- either they work or they don't. Consequently, psychiatry is another specialty that has had to think about how to handle the variability in potency among generics. Mic... Ψ Dare To Dream... blogs http://www.medworm.com/rss/comments.php?id=4060671 Tue, 22 Sep 2009 01:53:11 +0100 4060671 http://www.medworm.com/index.php?rid=2442582&cid=t_145620_136_f&fid=36032&url=http%3A%2F%2Fwww.everydayhealth.com%2Fblog%2Flife-with-breast-cancer%2Freactions-to-cancer-and-focusing-on-a-cure%2F Cancer grows in healthy bodies. That is why it sometimes takes a long time before it is found. Cancer cells can be hiding and waiting to blossom and we don’t even know it. I didn’t smoke or drink and I got plenty of sleep and tried to eat healthy. I buckled my seat belt when I was in a car as a passenger or driver and took vitamins. Cancer had no right choosing my body.  Some of us feel that way and others berate themselves for not being more mindful of how they were treating their bodies. Either way, cancer is like a terrorist working its insidious devious plan while we go about our lives unaware. We know that keeping our weight down helps reduce the risk for breast cancer. We know that eating less meat and avoiding alcohol also helps reduce our risk. Outside of that, we don’t know... Life with Breast Cancer blogs http://www.medworm.com/rss/comments.php?id=2442582 Wed, 20 May 2009 18:53:09 +0100 2442582 http://www.medworm.com/index.php?rid=4060686&cid=t_145620_109_f&fid=34859&url=http%3A%2F%2Fblog.davemsw.com%2Farchives%2F2009%2F03%2Fbiochemical_roots_of_depression_challenged.php Image via Wikipedia Not surprisingly,the biochemical theory regarding "chemical imbalance" is under attack again. The theory has always been an oversimplification of actual research data. All the research has said is that (1) anti-depressants have worked on average slightly better than placebo and (2) anti-depressants and therapy works slightly better than one or the other alone. Key to understanding what this means are the words "on average", "placebo" and "slightly better". On average, some people did not benefit from anti-depressants, and some did. Some experienced more benefit than others. Anti-depressants, I believe, are over prescribed mainly because clients don't want to invest the time and emotional energy in therapy. People don't want to see themselves as, in part, responsible ... Ψ Dare To Dream... blogs http://www.medworm.com/rss/comments.php?id=4060686 Sun, 29 Mar 2009 18:31:23 +0100 4060686 http://www.medworm.com/index.php?rid=2268014&cid=t_145620_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2009%2F03%2F15%2Fcan-fda-approved-hiv-drugs-treat-chemoresistant-ovarian-cancer%2F Two recent in vitro studies conducted in the U.S. and Europe raise a provocative question:  Can FDA-approved human immunodeficiency virus (HIV) drugs be used to treat chemoresistant ovarian cancer?  Both studies were based upon the fact that HIV patients taking antiretroviral inhibitors have a lower incidence of infection-associated malignancies.  Based upon that fact, the researchers [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=2268014 Mon, 16 Mar 2009 04:26:23 +0100 2268014 http://www.medworm.com/index.php?rid=1773566&cid=t_145620_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2008%2F09%2F07%2Fmk-0457-alone-and-in-combination-with-docetaxel-inhibits-ovarian-cancer-growth-in-vivo%2F …[T]he [M.D. Anderson Cancer Center & Baylor College of Medicine] researchers concluded that [Aurora kinase] AK inhibition [produced by MK-0457] significantly reduces ovarian cancer tumor burden and cell proliferation, and increases tumor cell apoptosis in preclinical ovarian cancer mouse models. The researchers noted that the role of Aurora kinase inhibition in ovarian cancer merits further [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=1773566 Mon, 08 Sep 2008 00:49:39 +0100 1773566 http://www.medworm.com/index.php?rid=1015095&cid=t_145620_136_f&fid=36032&url=http%3A%2F%2Fblog.healthtalk.com%2Fbreast-cancer%2Flife-with-breast-cancer%2Ftaking-breast-cancer-treatment-to-heart%2F The Big Guy (my 16-year-old son) was getting his hair cut on Saturday when I picked up a magazine in the waiting area to leaf through. I did something I don’t do very often; I ripped out a page - not just any page, but the “On Health” page from the U.S. News and World Report Magazine from October 29, 2007. Dr. Bernadine Healy had written an article entitled “The Heart after Breast Cancer.” See why I needed that page? Now you can forgive me for mutilating a magazine at the hair salon. She started by pointing out the incredibly good news released late October proclaiming the fall in death rates from breast cancer between 1993 and 2002. Then she dropped her bombshell; “…as breast cancer deaths move down, heart attacks and heart failure risk related to the curative treatments inc... Life with Breast Cancer blogs http://www.medworm.com/rss/comments.php?id=1015095 Thu, 08 Nov 2007 18:10:42 +0100 1015095 http://www.medworm.com/index.php?rid=904622&cid=t_145620_109_f&fid=35671&url=http%3A%2F%2Fwww.anxietyinsights.info%2Ftrip_antidepressant_caused_significant_weight_loss_in_clin.htm Participants in a clinical trial of DOV Pharmaceutical's triple reuptake inhibitor (TRIP) under development to treat depression and obesity, DOV 21,947, recorded significant reductions in body weight, Body Mass Index (BMI) scores and plasma triglyceride levels. The double-blind, placebo-controlled Phase Ib study enrolled 46 male and female volunteers. Following a one-week placebo run-in, subjects received either escalating daily doses of 50 mg, 100 mg and 150 mg of DOV 21,947 (n=31) or placebo (n=15), for a total of eight weeks. Those subjects with detectable blood levels of DOV 21,947 or its principal metabolite during at least three of four bimonthly visits (approximately 70% of the drug-treated subjects) were classified as drug compliant. At the end of this eight-week study, the mean di... Latest entries from www.anxietyinsights.info blogs http://www.medworm.com/rss/comments.php?id=904622 Wed, 26 Sep 2007 08:52:00 +0100 904622 http://www.medworm.com/index.php?rid=885539&cid=t_145620_136_f&fid=36032&url=http%3A%2F%2Fblog.healthtalk.com%2Fbreast-cancer%2Flife-with-breast-cancer%2Fgetting-to-know-your-cancer-drugs%2F It has been about a year since I stopped taking Arimidex, an aromatase inhibitor. The side effects I experienced are long gone. Gone are the horrendous aches and pains I had in my joints and bones. When I finally made the decision to stop, it had gotten to the point where it hurt to walk and even get up in the morning. For me the decision wasn’t difficult. As I have told you before, I insisted my oncologist put me back on Tamoxifen, which is still a viable drug in reducing cancer risk. For some of you the decision to stop an armoatase inhibitor isn’t so easy; the cancer may be more advanced or the fear of the return of cancer is overwhelming. There is still no counter evidence to suggest other than the effectiveness of aromatase inhibitors like Arimidex (anastrozole) and Femara (letroz... Life with Breast Cancer blogs http://www.medworm.com/rss/comments.php?id=885539 Thu, 20 Sep 2007 00:27:34 +0100 885539 http://www.medworm.com/index.php?rid=2510404&cid=t_145620_87_f&fid=34866&url=http%3A%2F%2Fwww.thecardioblog.com%2F2007%2F09%2F07%2Fwhy-vioxx-is-so-dangerous%2F This study was not considered conclusive, but if you have questions or concerns about medications you're currently taking speak with your doctor.Read | Permalink | Email this | Linking Blogs | Comments (Source: The Cardio Blog) The Cardio Blog blogs http://www.medworm.com/rss/comments.php?id=2510404 Thu, 06 Sep 2007 23:00:00 +0100 2510404 http://www.medworm.com/index.php?rid=579656&cid=t_145620_137_f&fid=35350&url=http%3A%2F%2Fwww.tangledneuron.info%2Fthe_tangled_neuron%2F2007%2F04%2Fcognitive_rehab.html Summary: Results of a small trial show cognitive rehabilitation can help people with mild Alzheimer’s improve their ability to perform practical tasks. Unlike cognitive stimulation programs, cognitive rehabilitation is designed to improve specific skills. Rehabilitation may help people with memory loss stay functional and independent, but more research is needed. Morris Friedell was diagnosed with Alzheimer’s disease in 1998. “I had a feeling that all I could do was wait for the axes to fall, one after the other,” the retired sociology professor wrote in his year 2000 essay “Potential for Rehabilitation in Alzheimer’s Disease.” “I’d lose my ability to drive, to budget, to speak coherently, to dress myself, to use the toilet. I thought: I must plan to die when I can stil... The Tangled Neuron blogs http://www.medworm.com/rss/comments.php?id=579656 Mon, 30 Apr 2007 19:16:47 +0100 579656